PMID- 30666204
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231104
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 9
DP  - 2018
TI  - Standard-Dose Proton Pump Inhibitors in the Initial Non-eradication Treatment of 
      Duodenal Ulcer: Systematic Review, Network Meta-Analysis, and Cost-Effectiveness 
      Analysis.
PG  - 1512
LID - 10.3389/fphar.2018.01512 [doi]
LID - 1512
AB  - Background: Short-term use of standard-dose proton pump inhibitors (PPIs) is the 
      first-line initial non-eradication treatment for duodenal ulcer (DU), but the 
      choice on individual PPI drug is still controversial. The purpose of this study 
      is to compare the efficacy, safety, and cost-effectiveness of standard-dose PPI 
      medications in the initial non-eradication treatment of DU. Methods: We searched 
      PubMed, Embase, Cochrane Library, Clinicaltrials.gov, China National Knowledge 
      Infrastructure, VIP database, and the Wanfang database from their earliest 
      records to September 2017. Randomized controlled trials (RCTs) evaluating 
      omeprazole (20 mg/day), pantoprazole (40 mg/day), lansoprazole (30 mg/day), 
      rabeprazole (20 mg/day), ilaprazole (10 mg/day), ranitidine (300 mg/day), 
      famotidine (40 mg/day), or placebo for DU were included. The outcomes were 4-week 
      ulcer healing rate (4-UHR) and the incidence of adverse events (AEs). A network 
      meta-analysis (NMA) using a Bayesian random effects model was conducted, and a 
      cost-effectiveness analysis using a decision tree was performed from the payer's 
      perspective over 1 year. Results: A total of 62 RCTs involving 10,339 
      participants (eight interventions) were included. The NMA showed that all the 
      PPIs significantly increased the 4-UHR compared to H(2) receptor antagonists 
      (H(2)RA) and placebo, while there was no significant difference for 4-UHR among 
      PPIs. As to the incidence of AEs, no significant difference was observed among 
      PPIs, H(2)RA, and placebo during 4-week follow-up. Based on the costs of both 
      PPIs and management of AEs in China, the incremental cost-effectiveness ratio per 
      quality-adjusted life year (in US dollars) for pantoprazole, lansoprazole, 
      rabeprazole, and ilaprazole compared to omeprazole corresponded to $5134.67, 
      $17801.67, $25488.31, and $44572.22, respectively. Conclusion: Although the 
      efficacy and tolerance of different PPIs are similar in the initial 
      non-eradication treatment of DU, pantoprazole (40 mg/day) seems to be the most 
      cost-effective option in China.
FAU - Zhang, Jiaxing
AU  - Zhang J
AD  - Department of Pharmacy, Guizhou Provincial People's Hospital, Guiyang, China.
FAU - Ge, Long
AU  - Ge L
AD  - First Clinical Medical College, Lanzhou University, Lanzhou, China.
FAU - Hill, Matt
AU  - Hill M
AD  - Health Outcomes and Pharmacy Practice, College of Pharmacy, The University of 
      Texas at Austin, Austin, TX, United States.
FAU - Liang, Yi
AU  - Liang Y
AD  - Health Outcomes and Pharmacy Practice, College of Pharmacy, The University of 
      Texas at Austin, Austin, TX, United States.
FAU - Xie, Juan
AU  - Xie J
AD  - Department of Pharmacy, Guizhou Provincial People's Hospital, Guiyang, China.
FAU - Cui, Dejun
AU  - Cui D
AD  - Department of Gastroenterology, Guizhou Provincial People's Hospital, Guiyang, 
      China.
FAU - Li, Xiaosi
AU  - Li X
AD  - Department of Pharmacy, Hospital of Chengdu Office of People's Government of 
      Tibetan Autonomous Region, Chengdu, China.
FAU - Zheng, Wenyi
AU  - Zheng W
AD  - Experimental Cancer Medicine, Clinical Research Center, Department of Laboratory 
      Medicine, Karolinska Institute, Stockholm, Sweden.
FAU - He, Rui
AU  - He R
AD  - Experimental Cancer Medicine, Clinical Research Center, Department of Laboratory 
      Medicine, Karolinska Institute, Stockholm, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20190107
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC6330312
OTO - NOTNLM
OT  - cost-effectiveness analysis
OT  - duodenal ulcer
OT  - network meta-analysis
OT  - proton pump inhibitors
OT  - systematic review
EDAT- 2019/01/23 06:00
MHDA- 2019/01/23 06:01
PMCR- 2019/01/07
CRDT- 2019/01/23 06:00
PHST- 2018/11/02 00:00 [received]
PHST- 2018/12/10 00:00 [accepted]
PHST- 2019/01/23 06:00 [entrez]
PHST- 2019/01/23 06:00 [pubmed]
PHST- 2019/01/23 06:01 [medline]
PHST- 2019/01/07 00:00 [pmc-release]
AID - 10.3389/fphar.2018.01512 [doi]
PST - epublish
SO  - Front Pharmacol. 2019 Jan 7;9:1512. doi: 10.3389/fphar.2018.01512. eCollection 
      2018.